TOP - May 2014, Vol 7, No 2
The Cancer Genome Atlas (TCGA) project now includes a recently reported comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma.
Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). These results of a randomized phase 3 trial (CA184-043) were presented at the 2014 Genitourinary Cancers Symposium.
Enzalutamide prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), according to complete results from the phase 3 PREVAIL trial.
Phase 3 data from a global clinical trial indicated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab was added to chemotherapy as second-line therapy in patients with advanced gastric cancer.
With little information in the literature, pharmacists and oncologists may feel insecure about the use of chemotherapy in a pregnant patient.
Recent advances in molecular technologies have enabled the dissection of inhibitory pathways within tumors and identification of inflammatory signals within the tumor microenvironment that regulate host immune responses.
In 2010, Dr Thomas Frieden, director of the Centers for Disease Control and Prevention (CDC), chose the 6 original health priorities that he would call “winnable battles.”
A dual vaccine strategy improved survival more than single vaccination of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Data from a randomized phase 2 trial were reported by Dung T. Le, MD, at the 2014 Gastrointestinal Cancers Symposium.
Many molecularly targeted agents that inhibit different pathways of hepatocarcinogenesis are under clinical development, and novel targets are being assessed in hepatocellular carcinoma (HCC). These efforts were described by Andrew X. Zhu, MD, PhD, at the 2014 Gastrointestinal Cancers Symposium.
To commemorate the 50th anniversary of the US Surgeon General’s report on the dangers of tobacco, the AACR published a policy statement on tobacco use by cancer patients to coincide with its 2014 annual meeting.
